Background: The diagnosis of chronic obstructive pulmonary disease (COPD) is often based on spirometry, which is not sensitive to early emphysema. We have recently described a method for assessing distal airspace dimensions by measuring recovery of nanoparticles in exhaled air after a single-breath inhalation followed by breath-hold. Recovery refers to the non-deposited particle fraction. The aim of this study was to explore differences in the recovery of exhaled nanoparticles in subjects with COPD and never-smoking controls. A secondary aim was to determine whether recovery correlates with the extent of emphysema. Method: A total of 19 patients with COPD and 19 controls underwent three repeats of single-breath nanoparticle inhalation followed by breath-hold. Particle concentrations in the inhaled aerosol, and in an alveolar sample exhaled after breathhold, were measured to obtain recovery. Findings: The patients with COPD had a significantly higher mean recovery than controls, 0Á128 AE 0Á063 versus 0Á074 AE 0Á058; P = 0Á010. Also, recovery correlated significantly with computed tomography (CT) densitometry variables (P<0Á01) and diffusing capacity for carbon monoxide (D L,CO ; P = 0Á002). Interpretation: Higher recovery for emphysema patients, relative to controls, is explained by larger diffusion distances in enlarged distal airspaces. The nanoparticle inhalation method shows potential to be developed towards a tool to diagnose emphysema.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common global cause of morbidity and mortality, with a large disease burden in developing countries (Adeloye et al., 2015) . As observed already by Burrows et al. (1966) , patients with COPD may have a predominantly bronchial disease or emphysema. The diagnosis is currently based on a history of exposure to noxious inhalants, symptoms of cough or shortness of breath, and spirometric evidence of airflow obstruction after bronchodilation (Celli & MacNee, 2004) . Spirometry is, however, relatively insensitive to early emphysema (Kuwano et al., 1990; Tylen et al., 2000; Regan et al., 2015) . There is evidence suggesting early diagnosis and intervention are beneficial for preserving lung function and reducing healthcare costs (Camilli et al., 1987; Zhou et al., 2010; Tawara et al., 2015) .
Hence, there is a need for a simple, easily accessible diagnostic method to detect emphysema. In this paper, we investigate a new, single-breath nanoparticle inhalation method, which could potentially be used to find early emphysema in clinical outpatient settings (Jakobsson et al., 2016; L€ ondahl et al., 2017) .
Due to their small size, inhaled nanoparticles easily traverse to distal airspaces, where they are deposited almost exclusively by diffusion (Schulz et al., 1992; Verbanck & Paiva, 2011) . The probability of deposition there depends on the residence time in the lung, and the distance to a surface. If time is kept constant, we expect enlarged distal airspaces to give rise to a lower than normal nanoparticle deposition. The term recovery is used to describe the fraction of particles returned with the exhaled gas; it is defined as the ratio of the particle number concentration in the expired gas to the particle number concentration in inhaled gas. ('Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection' 1994; Hinds, 1999) Thus, in emphysematous, enlarged distal airspaces, nanoparticle recovery is expected to be increased relative to normal. In a previous study, the method has shown to correlate with pulmonary tissue density in healthy volunteers (Aaltonen et al., 2018) .
The aim of this proof-of-concept study was to explore the difference in nanoparticle recovery between patients with COPD and never-smoking controls in an alveolar gas sample. A secondary aim was to examine whether the recovery values correlate with the extent of emphysema measured by computed tomography (CT) densitometry and diffusing capacity for carbon monoxide (D L,CO ). We also investigated the relationship between recovery and forced expiratory flow in one second (FEV 1 ).
Method
The study group consisted of 23 patients with COPD prospectively recruited from the Department of Respiratory Medicine at Sk ane University Hospital in Malm€ o, Sweden, as well as a local primary healthcare clinic. COPD was defined using Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. (From the Global Strategy for the Diagnosis) The control group consisted of a conveniency sample of 20 neversmokers without a history of pulmonary disease. The control group was similar to the COPD patients with respect to age and gender; the controls were subjectively healthy with no history of pulmonary disease. Never-smoker was defined as having no previous history of regular cigarette smoking for more than 1 year. The participants were recruited between March 2014 and September 2015.
Nanoparticle recovery was measured using Airspace Dimension Assessment with nanoparticles (AiDA) method (Fig. 1) . The instrument, the procedure as well as the theoretical background are described in detail elsewhere (Jakobsson et al., 2016; L€ ondahl et al., 2017) . Briefly, each measurement was carried out in sitting position during an inhalation followed by breath-holding for a given time, using a protocol similar to that of measuring D L,CO (Macintyre et al., 2005) . The subject first inhaled several breaths of particle-free air through a mouthpiece connected to a computer-controlled four-way valve (as used in Master Screen PFT; Jaeger, Germany) and then exhaled to residual volume. The valves closed, leading nanoparticle aerosol from a reservoir to the mouthpiece. The subject then performed an inhalation to total lung capacity (TLC), held his breath for ten seconds and finally exhaled into a sample collector. The AiDA apparatus generated a monodisperse aerosol containing 50 nm polystyrene latex nanospheres using an electrospray aerosol generator (TSI model 3480; TSI Inc, Shoreview, MN, USA), followed by size selection by a differential mobility analyser (Model 3071; TSI GmbH, Aachen, Germany), and dilution with particle-free air. The aerosol was generated into a 10-l semi-flexible container. A constant flow of aerosol through the container was maintained to ensure a uniform particle concentration. A condensation particle counter (CPC, Model 3760; TSI Inc., Aachen, Germany) was used to measure the particle concentration in the inhaled and exhaled aerosol. The inhalation system in AiDA was temperature-controlled at 35°C to prevent water vapour condensation. All aerosol containing volumes and tubings were made of electrically conducting or antistatic material to minimize deposition due to electrostatic attraction. In addition, the inhaled aerosol particles were singly (positively) charged, and thus only weakly interacting with electrical fields. The particles were hydrophobic to avoid hygroscopic particle growth (L€ ondahl et al., 2014) .
After accounting for particle losses within the instrument, particle concentration values in the inhaled and exhaled aerosol were used to determine recovery. The volumetric lung depth for the exhaled sample was chosen to be 1100-1300 ml. All subjects performed three repeated measurements, lasting approximately one minute each. The recovery values were normalized to 13s-effective breath-hold time, analogous to the procedure for measuring D L,CO (Macintyre et al., 2005) . The protocol resulted in an exposure to aerosol with a particle number concentration of 10 4 particles cm À3 and a deposited particle mass of <0Á03 lg in the lungs. The COPD group underwent CT scans of the chest. The scans were performed in suspended full inspiration using a multidetector-row scanner (Siemens Somatom Definition Flash; Siemens Healthcare, Forchheim, Germany), generating an exposure of 120 kV/15 mAs. A computer-assisted tissue density analysis was carried out using syngo.via Pulmo 3D software version VA, which automatically separated the lungs from adjacent organs. The extent of emphysema was estimated using two densitometric measures: Figure 1 The AiDA apparatus. More detailed description is given by Jakobsson and colleagues (Jakobsson et al., 2016) . 1 The relative volume of voxels with x-ray attenuation values below -950 Hounsfield Units (RV-950) 2 The lung density at the 15th percentile of the attenuation distribution histogram, termed partial density (PD15), given as gram per litre (M€ uller et al., 1988; Gevenois et al., 1995 Gevenois et al., , 1996 .
The CT scans were also visually assessed by a radiologist with 9 years of experience and a radiology resident with 2 years of experience. The extent of emphysema was graded as absent, mild, moderate or severe. Also, the presence of bullous emphysema, bronchiectasis and extensive bronchial wall thickening was evaluated.
Each subject underwent conventional lung function tests performed according to the European Respiratory Society/ American Thoracic Society guidelines. Postbronchodilator FEV 1 , vital capacity (VC) and D L,CO values were measured (Jaeger MasterScreen PFT, IntraMedic, Sollentuna, Sweden). Lung function variables were presented as percentage of predicted values (Miller et al., 2005) .
The study was approved by the Regional Ethical Review Board in Lund, Sweden, and the local radiation protection committee; it was performed in accordance to the Declaration of Helsinki, including informed written consent from all subjects. All investigations were conducted in Sk ane University Hospital, Malm€ o, Sweden.
Data analysis was performed with IBM SPSS Statistics 22 (2013). Data were, unless otherwise specified, reported as mean, standard deviation and range. Chi-squared test was used for sex differences. The recovery values were reported as mean and intra-individual standard deviation of three technically acceptable tests. The intra-individual variability was evaluated by coefficient of variation. The difference between the groups was assessed with independent sample t-tests. Relationships between the parameters were evaluated using the Spearman's q correlation. The requested level of significance was P less than 0Á05 for all statistical tests.
Results
Of the 23 COPD subjects initially included, four were excluded due to poor quality of AiDA measurements. Of these, three due to inhaled volume below 2/3 of vital capacity and one due to effective breath-hold time exceeding 17 s were excluded. One control subject was excluded due to spirometry indicating GOLD stage 2 COPD. Thus, 19 COPD subjects and 19 controls were eligible for analysis (Table 1) .
Nanoparticle recovery was significantly higher (and thus, deposition lower) in the COPD group relative to controls (Table 1, Fig. 2 ). The coefficient of variation for the recovery measurements was 11% (12% for the COPD group and 10% for controls).
The recovery of nanoparticles correlated with extent of emphysema as assessed with both CT and D L,CO (Fig. 3) . Considering the COPD group, in which CT was available, significant correlations were found between recovery and RV-950 (q = 0Á586; P = 0Á008), as well as between recovery and PD15 (q = À0Á665, P = 0Á003). A significant correlation between recovery and D L,CO , expressed as a percentage of predicted, was observed when considering only the COPD group (q = À0Á668; P = 0Á002). A similar result was obtained when all subjects were considered (q = À0Á506; P = 0Á001). No significant correlation between recovery and FEV 1 was found, neither considering only the COPD group (q = À0Á084, P = 0Á732) nor all subjects (q = À0Á285, P = 0Á083; Fig. 3 ). A significant correlation was found between D L,CO and PD15 (q = 0Á517, P = 0Á028), but the correlation between D L,CO and RV-950 was not statistically significant (q = 0Á406; P = 0Á095).
Discussion
This is the first experimental study showing nanoparticle deposition may be able to separate emphysema patients from healthy subjects. Mathematical models have suggested that nanoparticle deposition would be lower in emphysema subjects compared to healthy individuals (Sturm & Hofmann, 2004) . Presently, there are only a few experimental studies of nanoparticle deposition in patients with COPD (Anderson et al., 1990; Brown et al., 2002; M€ oller et al., 2008; L€ ondahl et al., 2012) . In most of these studies, the patients have not been characterized with respect to bronchial disease and emphysema. In a previous study, diesel exhaust particle deposition was lower in patients with COPD than healthy individuals, with the largest difference in the interval 20-50 nm (L€ ondahl et al., 2012) . For this reason, we selected 50 nm particles to maximize a putative difference. The volumetric lung depth for the measurements was chosen to be deep enough to represent respiratory zone, yet shallow enough to ensure that elderly and patients with pulmonary illness would be able to comply with the protocol.
The most important factor influencing aerosol deposition probability in the lungs is the size of the particles. ('Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection' 1994) Hydrophobic spherical particles larger than about 0Á3 lm deposit mainly by gravitational settling and inertial impaction, while particles below this size belong to the diffusion-dominated size regime (L€ ondahl et al., 2014) . Unlike gas molecules, aerosol particles generally do not bounce after contact with a surface. Deposition by gravitational settling is highest in horizontally oriented narrow airspaces with long particle residence times. Deposition by impaction is, on the other hand, most efficient in the branching conducting airways with high flow velocities. Deposition by diffusion onto surfaces in the lungs does not depend on airway orientation with respect to the gravitational field or on change in direction of the airflow, but only on distance and residence time. Short distances and long residence times increase nanoparticle deposition. Nanoparticles in the range 10-300 nm deposit mainly in the gas exchange region of the lungs, beyond generation 15. Micrometre-sized particles have a more complex deposition pattern, which can be high in the conducting airways, especially during fast breathing manoeuvres or in patients with airflow obstructions (L€ ondahl et al., 2017) .
As the probability of deposition of nanoparticles in the lungs depends on the aerosol residence time and distance to the wall, recovery should reflect diffusion distances in the distal airspaces, given controlled residence time. Recovery in this study is determined by measuring particle concentration in an alveolar sample of exhaled gas.
Methods currently used to detect emphysema in a clinical setting include CT and D L,CO . In computed tomography, distal airspace enlargement gives rise to low lung density, which is detected as low x-ray attenuation. The percentile density CT densitometric method has been shown to correlate with the extent of emphysema in pathologic specimens (Gould et al., 1988) . In this study, there was a significant correlation between recovery and densitometric variables RV-950 and PD15, suggesting recovery may reflect the extent of emphysema (Fig. 3) . There may, however, be differences between the types of emphysema likely to be found with CT and AiDA; nanoparticle recovery may reflect homogeneously distributed emphysema in ventilated regions, while poorly ventilated, heterogeneously emphysematous regions, such as bullae, may not affect recovery. This could explain part of the scatter in the correlation between the CT variables and recovery. The number of patients with bullous emphysema in this study (five) was too small to allow for analysis. Reduced D L,CO , in combination with airflow obstruction, indicates the presence of emphysema. Reduced D L,CO may, however, also have other causes, and when spirometry is normal, the finding is non-specific. In this study, we found a highly significant correlation between nanoparticle recovery and D L,CO (Fig. 3) . This is to be expected, as some of the determinants of the uptake of carbon monoxide are also important for AiDA -both techniques depend on bulk flow delivery and diffusion in distal airspaces (Macintyre et al., 2005) . The D L,CO method, however, also depends on diffusion across the alveolar-capillary membrane and into the red blood cell, as well as on reaction with haemoglobin -factors not expected to affect the AiDA measurements. Thus, conceptually, nanoparticle recovery may reflect distal airspace enlargement more specifically than D L,CO , although further studies are required to investigate this relationship.
Previous studies have shown a correlation between the CT percentile density method (PD15) and D L,CO (Gould et al., 1991) . In this study, recovery tended to show stronger correlation to PD15 than D L,CO did. Furthermore, recovery correlated significantly with RV-950, while D L,CO did not. These findings might indicate that recovery reflects distal airspace enlargement more specifically than D L,CO. The findings, however, need to be further investigated in larger studies.
The correlation between recovery and FEV 1 was not significant. This finding could signal that recovery may reflect the emphysematous component of the COPD rather than bronchial abnormalities; nanoparticle recovery is considered to have a low sensitivity to changes in direction of the airflow and does not deposit by impaction (L€ ondahl et al., 2017) . Patients with predominantly bronchial disease could, therefore, be expected to have similar recovery results to healthy subjects. Larger studies in patients with bronchial wall thickening and bronchiectasis should be carried out to investigate this relationship.
In healthy subjects, AiDA has shown highly repeatable results with a within-session coefficient of variation of 5% (Jakobsson et al., 2016) . The present study yielded a higher coefficient of variation of 11% for nanoparticle recovery, possibly due to differences in subject demographics and higher morbidity; many subjects were elderly, and many patients had moderate to severe COPD. One patient was paraplegic and performed the measurements from a wheelchair. Also, the resistance of the breathing circuit was somewhat high, which may explain why adequate measurements could not be obtained in all subjects. In future studies, the ergonomics of the apparatus should be further improved to facilitate better measurement quality. Nevertheless, the variability may be considered equal to comparative methods, such as D L,CO (Macintyre et al., 2005) .
Analyses of deposition patterns of micrometre-sized particles have previously been suggested as a tool to find emphysema. These methods, extensively discussed by L€ ondahl et al. (2017) are conceptually different, as micrometre-sized particles deposit mainly by sedimentation. They have not yet resulted in widespread clinical applications, presumably due to cumbersome measurement procedures. The AiDA method is simpler in comparison. Also, as the AiDA method uses relatively simple technology, it could be made available in primary care, as well as in areas with limited healthcare resources.
As the measurements consist of three repeats of a singlebreath-hold inhalation, together with several cycles of particlefree air, the protocol resulted in a low exposure to nanoparticles, comparable to <3& of daily particle number exposure, and <0Á7& of daily particle mass exposure in a relatively clean urban setting (Hussein et al., 2013; Johnston et al., 2013) . Similar particles, but at a higher concentration, have previously been extensively used in determining mucociliary clearance (Foord et al., 1975) . Wiebert and colleagues showed no evidence of quantitatively important translocation of nanoparticles to the systemic circulation from the lungs (Wiebert et al., 2006) . This study is the first to explore the possible use of nanoparticles as an indicator of COPD. As such, it has obvious limitations. The sample size is small. As the study is exploratory in nature, and previous experimental data in the field are very limited, no statistical power analysis was performed. Also, in this study, we did not attempt to separate the results between patients with mainly conductive airway disease from those with parenchymal destruction.
Several aspects of the AiDA technique require further research, for example the optimal particle diameter, breathhold time and sample volume. To evaluate AiDA as a possible diagnostic tool, a diagnostic study has to be performed; specificity, sensitivity and discrimination value as well as the role of comorbidities should be assessed. From a clinical point of view, detection of emphysema may be most interesting at an early stage of COPD. In this study, only a few patients had mild disease. A diagnostic study among subjects with possible early emphysema, such as smokers, should be conducted. Additionally, the information from the AiDA measurements in this study is given as particle recovery rather than airspace dimension. It is, however, possible to estimate airspace radius in millimetres from the recovery values according to method described by L€ ondahl et al. (2017) . This calculation requires a minimum of two repeats of the above-described measurements at different breath-hold time periods, which was not performed in this study -the approach should, however, be incorporated in future studies. Also, the effect of bronchial disease, asthma and interstitial lung disease to the recovery of nanoparticles should be investigated.
Conclusion
The patients with COPD have significantly higher recovery of nanoparticles in exhaled gas after a single-breath aerosol inhalation followed by standardized breath-hold compared to neversmoking healthy controls. Recovery is significantly correlated to physiological and radiological parameters of emphysema. In this limited-sample proof-of-concept study, nanoparticle recovery analysis shows potential to be developed towards a tool to diagnose emphysema. Further studies in larger samples are needed to further investigate and validate the AiDA method.
